Skip to main content
TipRanks
Go Ultimate75% OFF

Novavax (0A3S) AI Stock Analysis

16 Followers
GB:0A3S

Novavax

(LSE:0A3S)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Sanofi partnership monetizationThe Sanofi alliance provides Novavax with meaningful non-product revenue, milestone potential, and validation from a major vaccine partner. Additional technology-transfer and commercial-launch milestones, plus royalties, could support funding and diversify commercialization beyond standalone COVID vaccine sales.
Negative Factors
Volatile and declining revenueThe sharp reversal in revenue and earnings indicates that Novavax has not yet established a stable commercial scale. Such volatility makes planning and investment more difficult, while renewed losses can limit internally funded development and increase reliance on milestones or other external revenue sources.

Novavax (0A3S) vs. iShares MSCI United Kingdom ETF (EWC)

-25%0%25%50%75%100%125%GB:0A3S+27.70%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.31B
Dividend Yield
―
Average Volume (3M)
117.11K
Price to Earnings (P/E)
-17.3
Beta (1Y)
0.81
Revenue Growth
-61.33%
EPS Growth
-121.87%
Country
UK
Employees
749
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Novavax Business Overview & Revenue Model

Company Description

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coro...

Novavax Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-23.11%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial progress in Sanofi partnership milestones, commercial activity, cash runway, cost reductions, revenue guidance, Matrix-M demand, and pipeline development. The main challenges were lower quarterly revenue due to declining R&D reimbursement, uncertainty around future COVID market dollars and partner timelines, potential non-cash write-offs, and the early-stage nature of the C. diff and oncology programs. Highlights significantly outweighed the lowlights.

Positive Updates

Sanofi Phase III Milestone and Partnership Progress
Sanofi initiated its Phase III influenza-COVID-19 combination vaccine trial in Europe, triggering a $125 million milestone for Novavax. Novavax is on track for an additional $75 million milestone upon completion of Sanofi's manufacturing technology transfer in mid-2027, and is eligible for a one-time $225 million milestone upon the first commercial sale of a CIC product in the U.S. The Sanofi agreement has generated over $1 billion in revenue for Novavax to date.

Negative Updates

Lower Third-Quarter Revenue
Third-quarter 2026 total revenue was $68 million, compared with $70 million in the prior-year quarter. The company cited a $42 million reduction in R&D reimbursement as it nears completion of its support for Sanofi's clinical and 2026/2027 COVID-season activities.

Company Guidance

Novavax raised its full year 2026 revenue framework by $145 million and expects adjusted total revenue of $400 million at midpoint with a range of between $385 million and $415 million; it expects full year 2026 combined GAAP R&D and SG&A of $385 million at midpoint, while reiterating a non-GAAP midpoint of $325 million and narrowing the range to $315 million-$335 million. It expects to include the $75 million Sanofi tech transfer milestone in the third quarter of 2027, while R&D reimbursement and Sanofi amortization are expected to become very small contributors to revenue and to end during 2027. Looking forward to 2028, it expects to reduce non-GAAP R&D and SG&A expenses by over 200 million, reflecting a greater than 50% decrease when compared to 2025, and separately has a target of $150 million-$200 million by 2028; it anticipates less than half the headcount as compared to the first quarter 2026 and is exploring an over 50% reduction to its operating footprint. This could result in non-cash fixed asset write-offs of up to 35 million during 2027 and could translate into 2027 GAAP combined R&D and SG&A of up to $265 million at midpoint; the company expects cash runway through and well into 2029, APA-era liabilities paid off by the first quarter of 2029, and a potential U.S. CIC commercial launch in 2029 triggering a $225 million milestone.

Novavax Risk Analysis

Novavax disclosed 69 risk factors in its most recent earnings report. Novavax reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Insider Trading ArrangementsQ3, 2026

Novavax Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A3S against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
VIRVIR68Neutral$1.58B-7.40-21.38%―1695.96%65.40%
ABCLABCL64Neutral$3.60B-23.08-15.35%―92.10%16.43%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ORICORIC44Neutral$831.45M-5.35-40.99%――15.37%
SANASANA44Neutral$563.31M-3.55-97.08%――45.15%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%GB:0A3SVIRORICABCLSANADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A3S and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A3SNovavax7.981.6926.88%
VIRVir Biotechnology, Inc.9.253.8170.04%
ORICOric Pharmaceuticals Inc8.00-3.48-30.31%
ABCLAbcellera Biologics, Inc.11.037.42205.54%
SANASana Biotechnology, Inc.1.88-1.52-44.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.